Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
URGN

UroGen Pharma Ltd

URGN

13.40USD+0.17 (+1.28%)Market Closed
Watchlist

Market Summary

USD13.40+0.17
Market Closed
1.28%

URGN Stock Price

View Fullscreen

URGN RSI Chart

URGN Valuation

Market Cap

414.1M

Price/Earnings (Trailing)

-3.94

Price/Sales (Trailing)

5.36

EV/EBITDA

-2.85

Price/Free Cashflow

-4.86

URGN Price/Sales (Trailing)

URGN Profitability

Operating Margin

87.65%

EBT Margin

-162.03%

Return on Equity

95.75%

Return on Assets

-98.8%

Free Cashflow Yield

-20.6%

URGN Fundamentals

URGN Revenue

Revenue (TTM)

77.3M

Revenue Y/Y

29.54%

Revenue Q/Q

-1.36%

URGN Earnings

Earnings (TTM)

-105.1M

Earnings Y/Y

15.3%

Earnings Q/Q

9.35%

Price Action

Last 7 days

4.4%

Last 30 days

17.4%

Last 90 days

-20.5%

Trailing 12 Months

56.0%

How does URGN drawdown profile look like?

URGN Financial Health

Current Ratio

3.8

URGN Investor Care

Shares Dilution (1Y)

34.35%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202368.0M72.5M77.3M0
202254.1M57.7M62.4M64.4M
202119.3M31.9M39.8M48.0M
202000011.8M
20190000
20188.6M9.0M1.5M1.1M
201715.2M12.8M10.5M8.2M
201600017.5M

Latest Insider Trading transactions for URGN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 31, 2023
smith jason drew
acquired
-
-
8,334
general counsel
Aug 31, 2023
smith jason drew
sold
-68,438
18.01
-3,800
general counsel
Jul 26, 2023
cohen fred e
acquired
661,494
9.54
69,339
-
Jan 31, 2023
schoenberg mark
acquired
-
-
3,833
chief medical officer
Jan 31, 2023
barrett elizabeth a.
acquired
-
-
18,333
chief executive officer
Jan 31, 2023
smith jason drew
sold
-16,556
10.12
-1,636
general counsel
Jan 31, 2023
smith jason drew
acquired
-
-
3,333
general counsel
Jan 31, 2023
schoenberg mark
sold
-19,228
10.12
-1,900
chief medical officer
Jan 20, 2023
schoenberg mark
acquired
613,385
5.00
122,677
chief medical officer
Oct 31, 2022
schoenberg mark
acquired
-
-
500
chief medical officer

1–10 of 50

Which funds bought or sold URGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 24, 2023
DEUTSCHE BANK AG\
added
666
133,111
147,301
-%
Nov 15, 2023
MORGAN STANLEY
added
76.52
905,326
1,556,890
-%
Nov 15, 2023
Opaleye Management Inc.
reduced
-43.86
-1,416,300
4,483,200
1.46%
Nov 15, 2023
GSA CAPITAL PARTNERS LLP
new
-
143,000
143,000
0.01%
Nov 15, 2023
Annandale Capital, LLC
reduced
-2.96
273,000
1,146,000
0.28%
Nov 15, 2023
JANE STREET GROUP, LLC
reduced
-24.69
2,675
140,899
-%
Nov 14, 2023
WELLINGTON MANAGEMENT GROUP LLP
new
-
981,582
981,582
-%
Nov 14, 2023
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-33.67
-6,877
60,481
-%
Nov 14, 2023
LAZARD ASSET MANAGEMENT LLC
new
-
46,000
46,000
-%
Nov 14, 2023
MILLENNIUM MANAGEMENT LLC
added
43.54
1,875,220
3,863,750
-%

1–10 of 46

Latest Funds Activity

Are funds buying URGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own URGN
No. of Funds

Schedule 13G FIlings of UroGen Pharma Ltd

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 15, 2023
great point partners llc
8.51%
2,620,545
SC 13G
Aug 04, 2023
monograph capital holdings advisors, llc
5.1%
1,572,327
SC 13D
Jun 12, 2023
menora mivtachim holdings ltd.
12.45%
2,919,002
SC 13G/A
Feb 13, 2023
stonepine capital management, llc
5.7%
1,304,947
SC 13G/A
Dec 01, 2022
stonepine capital management, llc
5.2%
1,196,908
SC 13G
Jul 08, 2022
blackrock inc.
1.5%
340,412
SC 13G
Feb 14, 2022
wildcat capital management, llc
2.4%
533,139
SC 13G/A
Feb 14, 2022
credit suisse ag/
4.84%
1,085,749
SC 13G/A
Feb 04, 2022
wellington management group llp
1.06%
238,008
SC 13G/A
Feb 03, 2022
blackrock inc.
7.7%
1,728,094
SC 13G/A

Recent SEC filings of UroGen Pharma Ltd

View All Filings
Date Filed Form Type Document
Nov 14, 2023
10-Q
Quarterly Report
Nov 14, 2023
8-K
Current Report
Nov 14, 2023
S-8
Employee Benefits Plan
Sep 15, 2023
EFFECT
EFFECT
Sep 15, 2023
SC 13G
Major Ownership Report
Sep 13, 2023
CORRESP
CORRESP
Sep 12, 2023
UPLOAD
UPLOAD
Sep 11, 2023
8-K
Current Report
Sep 08, 2023
4
Insider Trading
Sep 08, 2023
4
Insider Trading

Peers (Alternatives to UroGen Pharma Ltd)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
31.4B
-
4.92% 426363.59%
-3.6K
218.4K
- -102.45%
30.7B
10.7B
11.84% -53.56%
-8.86
2.88
-53.67% -129.46%
22.0B
1.7B
4.71% -20.32%
-43.06
12.74
79.37% 56.87%
17.7B
2.3B
23.54% -7.88%
120.62
7.68
15.05% 75.21%
12.4B
3.6B
1.56% -32.86%
29.22
3.44
8.35% -51.49%
MID-CAP
7.5B
272.9M
38.55% 34.32%
-12.3
27.31
141.38% 4.43%
5.6B
-
16.25% 246.63%
-9.66
48.33
54.84% -12.96%
3.5B
631.9M
-10.80% 43.56%
-23.57
5.55
23.54% 31.53%
3.3B
223.4M
11.07% -7.88%
-16.25
14.68
- -26.24%
2.6B
240.7M
-11.66% -25.68%
-12.44
10.6
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
7.85% -14.88%
24.07
4.29
81.69% -7.29%
662.5M
1.0B
-19.01% -66.75%
-1.21
0.63
-43.15% 58.48%
100.5M
6.4M
-2.56% -78.77%
-0.61
15.6
-44.11% 50.48%
42.3M
-
410.00% -4.38%
-0.65
-
- -29.23%
26.3M
-
17.86% 4717.52%
-0.55
-
- -13.74%

UroGen Pharma Ltd News

Latest updates
Yahoo Finance27 Nov 202308:00 am9 days ago
InvestorsObserver20 Nov 202303:27 pm16 days ago
Yahoo Finance30 Oct 202307:00 am37 days ago
MarketBeat11 Oct 202307:00 am56 days ago
Nasdaq09 Oct 202307:00 am58 days ago
Seeking Alpha24 Aug 202307:00 am3 months ago
The Wall Street Journal17 Aug 202307:00 am3 months ago
Yahoo Finance12 Aug 202307:00 am3 months ago
The Motley Fool28 Jul 202307:00 am4 months ago
英为财情 Investing.com28 Jul 202307:00 am4 months ago
Yahoo Finance25 Jul 202307:00 am4 months ago
Business Wire11 May 202307:00 am6 months ago
Business Wire16 Mar 202307:00 am8 months ago
Investing.com Россия30 Nov 202209:48 pm12 months ago
Business Wire11 Aug 202207:00 am16 months ago

Financials for UroGen Pharma Ltd

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-1.4%20,852,00021,139,00017,192,00018,092,00016,097,00016,604,00013,564,00016,174,00011,351,00013,032,0007,485,0007,966,0003,461,000372,000310,000248,000186,000124,00062,000-283,000
Cost Of Revenue-3.1%2,367,0002,443,0002,265,0002,263,0002,020,0001,846,0001,525,0001,589,0001,244,0001,427,000897,000652,000309,00048,000------1,055,000
Gross Profit-1.1%18,485,00018,696,00014,927,00015,829,00014,077,00014,758,00012,039,00014,585,00010,107,00011,605,0006,588,0007,314,0003,152,000324,000---18,000---772,000
  S&GA Expenses-3.3%21,755,00022,494,00024,474,00021,634,00019,071,00020,833,00021,300,00021,418,00021,624,00022,304,00022,189,00022,163,00022,065,00024,018,00021,973,00019,745,00013,972,00013,775,00012,707,00012,552,00010,743,000
  R&D Expenses-11.7%10,230,00011,584,00012,498,00014,477,00013,093,00012,640,00012,696,00013,082,00011,923,00012,124,00010,513,00012,405,00010,211,0008,106,00016,588,00020,094,0009,481,0009,996,0009,726,00011,465,0009,574,000
EBITDA Margin----1.61-1.66-1.70-1.93-2.05-2.26-2.72-3.36-6.20-10.14-14.99-80.63-76.24-76.32-53.65----
Income Taxes-116.7%-9,00054,00021,000689,000709,00032,000325,0001,137,000-312,000-3,374,000---------
Earnings Before Taxes9.1%-21,888,000-24,082,000-30,192,000-28,180,000-25,122,000-26,659,000-28,067,000-27,315,000-30,211,000-25,910,000-25,935,000-27,152,000-28,816,000-31,349,000-------
EBT Margin----1.62-1.68-1.72-1.95-2.06-2.28-2.74-3.38-6.49-10.60-15.70-84.27-80.39-80.39-57.75----
Net Income9.4%-21,879,000-24,136,000-30,213,000-28,869,000-25,831,000-26,691,000-28,392,000-28,452,000-30,211,000-26,222,000-25,935,000-30,526,000-28,816,000-31,349,000-37,793,000-38,973,000-22,252,000-22,477,000-21,444,000-23,716,000-20,533,000
Net Income Margin----1.64-1.71-1.75-1.97-2.09-2.31-2.83-3.49-6.05-10.89-17.86-87.61-92.89-80.39-68.72----
Free Cashflow----25,830,000-21,765,000-17,765,000-24,262,000-24,021,000-20,272,000-18,670,000-19,014,000-27,688,000-21,414,000-25,740,000-24,216,000-35,731,000-26,192,000-12,577,000----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets103.1%19495.0011313612814616612013515497.00122140161167202227239252104113
  Current Assets123.9%18281.0096.0012912214016111412514093.00116129130122149160191248102111
    Cash Equivalents492.8%11920.0037.0055.0029.0081.0010544.0055.0063.0040.0053.0025.0036.0026.0050.0066.0090.00247101109
  Inventory0.3%5.005.005.004.005.005.005.005.004.003.003.002.001.001.00-------
  Net PPE-9.6%1.001.001.001.002.002.002.002.002.002.002.002.002.001.001.001.001.001.001.001.001.00
Liabilities0.8%23623423022519218718311110397.0021.0026.0019.0018.0016.0022.0016.0014.0012.0013.009.00
  Current Liabilities-3.7%26.0027.0025.0024.0019.0018.0019.0022.0020.0019.0017.0021.0018.0016.0014.0019.0014.0012.0010.0013.009.00
    LT Debt, Non Current0.2%99.0098.0098.0098.0072.0071.0071.00--------------
Shareholder's Equity69.7%-41.99-138--89.36-63.29-40.91-8.0032.0056.0076.0096.0012114315018021122524090.00104
  Retained Earnings-3.5%-653-631-607-577-548-522-495-467-438-408-382-356-326-297-265-228-189-166-144-122-99.15
  Additional Paid-In Capital24.0%611493491488485481479476470465459453446439416408400391384213203
Shares Outstanding31.5%31.0024.0023.0023.0023.0023.0023.0023.0022.0022.0022.0022.0022.0021.0021.0021.0020.0021.0019.0016.0016.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations14.7%-17,299-20,274-25,807-21,752-17,612-24,199-23,996-20,070-18,476-18,945-27,401-21,242-25,080-23,929-35,635-26,000-12,528-14,555-17,934-10,284-9,279
  Share Based Compensation0.1%2,2242,2222,2862,3682,4402,8232,9495,3575,5156,0466,1956,5266,7637,1197,6178,0657,2437,2127,4478,8779,515
Cashflow From Investing-89.2%4013,7206,27023,108-35,493-15113,5969,12510,660-30,74015,02449,46513,23417,51413,0259,296-12,659-142,186-44.00-26.00-333
Cashflow From Financing81072.7%116,07714367125,3681,101-77.0070,742-32.00-16872,5154.0078.0061.0016,29890.002451,126373163,5062,200-14.00

URGN Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue$ 20,852$ 16,097$ 59,183$ 46,265
Cost of revenue2,3672,0207,0755,391
Gross profit18,48514,07752,10840,874
Operating expenses:    
Research and development expenses10,23013,09334,31238,429
Selling, general and administrative expenses21,75519,07168,72361,204
Operating loss(13,500)(18,087)(50,927)(58,759)
Financing on prepaid forward obligation(5,479)(4,819)(16,047)(16,478)
Interest expense on long-term debt(3,815)(2,694)(11,129)(5,215)
Interest and other income, net9064781,941604
Loss before income taxes(21,888)(25,122)(76,162)(79,848)
Income tax expense9(709)(66)(1,066)
Net Loss(21,879)(25,831)(76,228)(80,914)
Statements of Comprehensive Loss    
Net loss(21,879)(25,831)(76,228)(80,914)
Other comprehensive income (loss)    
Unrealized gain (loss) on investments20(99)(27)(130)
Comprehensive Loss$ (21,859)$ (25,930)$ (76,255)$ (81,044)
Net loss per ordinary share - basic and diluted (in dollars per share)$ (0.68)$ (1.13)$ (2.89)$ (3.56)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)32,298,18222,798,26326,358,71922,711,686

URGN Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 119,305$ 55,408
Marketable securities28,11444,556
Restricted cash817813
Accounts receivable12,84712,704
Inventories5,0024,325
Prepaid expenses and other current assets16,03811,101
Total current assets182,123128,907
Non-current assets:  
Property and equipment, net8231,297
Restricted deposit225223
Right of use assets1,9052,452
Marketable securities6,5070
Other non-current assets2,0502,740
Total Assets193,633135,619
Current liabilities:  
Accounts payable and accrued expenses14,08312,383
Employee related accrued expenses8,1528,257
Other current liabilities3,5533,276
Total current liabilities:25,78823,916
Non-current liabilities:  
Prepaid forward obligation107,27698,923
Long-term debt98,51897,537
Long-term lease liabilities1,0261,586
Uncertain tax positions liability3,0183,018
Total Liabilities235,626224,980
Commitments and Contingencies (Note 18)
Shareholders' Deficit:  
Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at September 30, 2023 and December 31, 2022; 30,854,778 and 23,129,953 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively8463
Additional paid-in capital611,389487,787
Accumulated deficit(653,332)(577,104)
Accumulated other comprehensive loss(134)(107)
Total Shareholders' Deficit(41,993)(89,361)
Total Liabilities and Shareholders' Deficit$ 193,633$ 135,619
URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
 CEO
 WEBSITEwww.urogen.com
 EMPLOYEES193

UroGen Pharma Ltd Frequently Asked Questions


What is the ticker symbol for UroGen Pharma Ltd? What does URGN stand for in stocks?

URGN is the stock ticker symbol of UroGen Pharma Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of UroGen Pharma Ltd (URGN)?

As of Wed Dec 06 2023, market cap of UroGen Pharma Ltd is 414.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of URGN stock?

You can check URGN's fair value in chart. The fair value of UroGen Pharma Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of UroGen Pharma Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for URGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is UroGen Pharma Ltd a good stock to buy?

The fair value guage provides a quick view whether URGN is over valued or under valued. Whether UroGen Pharma Ltd is cheap or expensive depends on the assumptions which impact UroGen Pharma Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for URGN.

What is UroGen Pharma Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 06 2023, URGN's PE ratio (Price to Earnings) is -3.94 and Price to Sales (PS) ratio is 5.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. URGN PE ratio will change depending on the future growth rate expectations of investors.